In line with these findings, a recent study has shown that Fc-fusion proteins of both WT IL-2 and an IL2Rα-biased IL-2v (N88D) more effectively expand tumor-antigen specific CD8+ T cells (TSTs) and induce more potent anti-tumor responses than a Fc fusion of an IL2Rβγc-biased IL-2v while also exhibiting better safety. The gene discussed is IL2; the disease is neoplasm.